Table 2.
Pre- and Post-operative change of IOP and antiglaucoma medications in the three groups
| Phaco-ExPRESS (n = 32) |
Phaco-Trab (n = 25) |
Trab (n = 32) |
P value | |
|---|---|---|---|---|
|
PRE-OP IOP (Mean ± SD) |
21.15 ± 8.27 | 24.21 ± 7.80 | 29.82 ± 11.32 |
†P = 0.23 ‡P = 0.03 §P < 0.01 |
|
POST-OP 2 W IOP (Mean ± SD) |
9.57 ± 3.16 | 11.56 ± 3.56 | 10.02 ± 4.21 |
†P = 0.05 ‡P = 0.12 §P = 0.63 |
|
POST-OP 1 M IOP (Mean ± SD) |
11.06 ± 3.15 | 12.81 ± 3.81 | 12.91 ± 4.47 |
†P = 0.10 ‡P = 0.93 §P = 0.06 |
|
POST-OP 3 M IOP (Mean ± SD) |
12.51 ± 3.21 | 13.08 ± 4.05 | 13.10 + 4.58 |
†P = 0.59 ‡P = 0.99 §P = 0.56 |
|
POST-OP 6 M IOP (Mean ± SD) |
12.49 ± 3.53 | 12.94 ± 3.54 | 12.54 ± 3.26 |
†P = 0.63 ‡P = 0.77 §P = 0.84 |
|
POST-OP 12 M IOP (Mean ± SD) |
13.14 ± 3.69 | 13.62 ± 3.84 | 12.37 ± 3.53 |
†P = 0.63 ‡P = 0.25 §P = 0.47 |
|
POST-OP 18 M IOP (Mean ± SD) |
12.71 ± 2.51 | 13.92 ± 3.87 | 12.93 ± 3.32 |
†P = 0.18 ‡P = 0.29 §P = 0.73 |
|
POST-OP 24 M IOP (Mean ± SD) |
13.17 ± 3.48 | 18.00 ± 3.38 | 12.90 ± 3.08 |
†P = 0.85 ‡P = 0.91 §P = 0.74 |
|
NO. of antiglaucoma medications at baseline (Mean ± SD) |
1.97 ± 1.12 | 2.24 + 0.94 | 3.00 ± 1.10 |
†P = 0.37 ‡P = 0.01 §P < 0.01 |
|
NO. of antiglaucoma medications at (Mean + SD) |
0.53 ± 0.84 | 1.32 ± 1.21 | 0.72 ± 0.99 |
†P = 0.04 ‡P = 0.03 §P = 0.46 |
The IOP preoperatively and postoperative 2 weeks (POST-OP 2 W), postoperative 1 month (POST-OP 1 M), postoperative 3 months (POST-OP 3 M), postoperative 6 months (POST-OP 6 M), postoperative 12 months (POST-OP 12 M), postoperative 18 months (POST-OP 18 M), postoperative 24 months (POST-OP 24 M), number of preoperative and postoperative anti-glaucoma medications. †: Phaco-ExPRESS vs. Phaco-Trab, ‡: Phaco-Trab vs. Trab, §: Phaco-ExPRESS vs. Trab. A p-value < 0.05 was considered as statistically significant. For preoperative IOP, the Phaco-ExPRESS group showed lower IOP than the Trab group (p < 0.01). No statistical significance was found in postoperative IOP from 2 weeks to 24 months among the three groups. However, for preoperative anti-glaucoma medications, the Trab group showed a higher number of anti-glaucoma medications than the other two groups (p < 0.05). As for postoperative anti-glaucoma medications, no significant difference was found between the Phaco-ExPRSS group and the Trab group, whereas the Phaco-Trab group showed higher number of medications than the other two groups (p < 0.05)